Chemotherapy

FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

FDA OKs 1st Biosimilar to Prevent Chemo-Related Infections

Fulphila, biosimilar to Neulasta, helps reduce risk of infection during cancer treatment.

Neoadjuvant Chemo vs TUR Before RC Ups Survival

Neoadjuvant Chemo vs TUR Before RC Ups Survival

By

Study findings suggest that clinicians should use neoadjuvant chemotherapy in many more muscle-invasive bladder cancer patients.

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer

Chemo, Immunotherapy Feasible in Metastatic Bladder Cancer

One-year overall survival of 61% for gemcitabine and cisplatin plus ipilimumab.

Peripherally Inserted Central Catheter Commonly Used Short-Term

Peripherally Inserted Central Catheter Commonly Used Short-Term

Among patients with short-term peripherally inserted central catheter, about 1 in 10 has a complication

Commercial Insurers' Coverage of Infused Chemo Varies by Setting

Commercial Insurers' Coverage of Infused Chemo Varies by Setting

Better reimbursement at hospital outpatient depts, even though drug-level costs lower in doctor's office

Cancer Treatments Can Have Effects on Aging Phenotypes

Cancer Treatments Can Have Effects on Aging Phenotypes

Certain chemotherapies might shorten telomeres and alter microRNA.

Oral Chemo Parity Laws Offer Some Financial Safeguards

Oral Chemo Parity Laws Offer Some Financial Safeguards

Decrease in estimated out-of-pocket spending at the 25th, 50th, 75th percentiles; increase at 90th, 95th

Bladder Preservation Therapy Linked With Reduced Survival in MIBC

Bladder Preservation Therapy Linked With Reduced Survival in MIBC

By

Radical cystectomy is associated with better survival, but findings suggest BPT may produce acceptable oncologic outcomes in appropriately selected patients.

Immunization Recommendations for Chemotherapy Patients

Immunization Recommendations for Chemotherapy Patients

Which vaccines should be avoided in patients receiving chemotherapy?

Survival Up With Patient-Reported Symptom Monitoring During Chemo

Survival Up With Patient-Reported Symptom Monitoring During Chemo

The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively.

Real-World mUCB Patient Survival Worse Than in Clinical Trials

Real-World mUCB Patient Survival Worse Than in Clinical Trials

By

Just 1 in 4 patients diagnosed with metastatic urothelial carcinoma of the bladder survive for a year, according to US national registry data.

Neoadjuvant Chemo Benefits Some Variant MIBC Patients

Neoadjuvant Chemo Benefits Some Variant MIBC Patients

By

Researchers find prolonged survival among patients with neuroendocrine muscle-invasive bladder cancer.

Post-chemo PD-L1 Tied to Worse Prognosis in Bladder Cancer Pts

Post-chemo PD-L1 Tied to Worse Prognosis in Bladder Cancer Pts

By

Five-year cancer-specific survival rates were 48.1% and 69.6% for PD-L1 positive and negative patients, respectively.

Neurofeedback Effective for Chemo-Induced Nerve Damage

Neurofeedback Effective for Chemo-Induced Nerve Damage

The NFB group demonstrated greater improvement than the controls on the Brief Pain Interval program.

Pre-Cystectomy Chemo Does Not Up Survival in 'Real World' Setting

Pre-Cystectomy Chemo Does Not Up Survival in 'Real World' Setting

By

Finding contrasts with results of randomized clinical trials.

Bacteria,Fungi Discovered in Medical Marijuana

Bacteria,Fungi Discovered in Medical Marijuana

A patient developed a rare and incurable fungal infection after using aerosolized marijuana and ultimately died.

Chemotherapy Use for Upper Tract Urothelial Carcinoma Increasing

Chemotherapy Use for Upper Tract Urothelial Carcinoma Increasing

By

The proportion of patients receiving neoadjuvant chemotherapy in the United States rose from 0.6% to 2.7% between 2004 and 2013.

Thromboembolic Events Common With Neoadjuvant Chemo for MIBC

Thromboembolic Events Common With Neoadjuvant Chemo for MIBC

Before and after radical cystectomy, thromboembolic events are common in bladder cancer patients who undergo neoadjuvant chemotherapy.

Therapeutic Sequences for mCRPC Probed

Therapeutic Sequences for mCRPC Probed

By

Researchers demonstrate a possible survival advantage by including cabazitaxel in sequences of new agents in the post-docetaxel setting.

Cisplatin Dose Linked to Hearing Loss in Cancer Survivors

Cisplatin Dose Linked to Hearing Loss in Cancer Survivors

Severe to profound hearing loss seen in 18% of male germ cell tumor survivors.

New Study Supports Use of Trimodal Therapy for MIBC

New Study Supports Use of Trimodal Therapy for MIBC

By

Researchers find no difference in 5-year disease-specific survival between multi-disciplinary bladder-sparing approach and radical cystectomy.

Gender Differences in Chemotherapy for Stage IV Bladder Cancer

Gender Differences in Chemotherapy for Stage IV Bladder Cancer

Women with stage IV bladder cancer have a lower median overall survival rate when compared to men.

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

Adjuvant Docetaxel Does Not Help Biochemical DFS in High-risk PCa

In prostate cancer, adjuvant docetaxel without hormone therapy did not improve biochemical disease-free survival after radical prostatectomy.

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

Model Predicts Chemotherapy Toxicity in Solid Tumor Patients

A predictive model for chemotherapy toxicity found that 58% of patients experienced grade 3 toxicity or higher.

Neoadjuvant Chemo Rarely Used in Upper Tract Urothelial Cancer

Neoadjuvant Chemo Rarely Used in Upper Tract Urothelial Cancer

By

Therapy used in less than 5% of cases, even in those with higher clinical stage.

ASCO Endorses European Guideline on Bladder Cancer

ASCO Endorses European Guideline on Bladder Cancer

The guidelines were assessed for developmental rigor, and the ASCO endorsed all but one of the guidelines.

Vitamin E Protects Against Cisplatin-induced Hearing Loss

Vitamin E Protects Against Cisplatin-induced Hearing Loss

Placebo group had significant hearing loss at one month at both 2,000 HZ and 8,000 HZ.

Adjuvant Chemo Ups Survival in Locally Advanced Bladder Cancer

Adjuvant Chemo Ups Survival in Locally Advanced Bladder Cancer

Improved survival with adjuvant chemotherapy in patients with locally advanced disease compared with cystectomy alone.

Bladder Tumor Resection Key to Cystectomy Outcomes

Bladder Tumor Resection Key to Cystectomy Outcomes

By

Researchers estimate that 40% of pathologic response in MIBC patients receiving both neoadjuvant chemo and TURBT is due to TURBT.

Initial Gleason Score Does Not Predict Abiraterone Efficacy in mCRPC

Initial Gleason Score Does Not Predict Abiraterone Efficacy in mCRPC

Overall survival and radiographic progression-free survival trends demonstrate treatment benefit of abiraterone acetate in prostate cancer.

Sign Up for Free e-newsletters